{"id":"W2789253089","doi":"10.1158/1538-7445.sabcs17-ot3-06-07","title":"Abstract OT3-06-07: A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Fulvestrant; Medicine; Bromodomain; Tolerability; Breast cancer; Estrogen receptor; Pharmacodynamics; Pharmacology; Metastatic breast cancer; Oncology; Internal medicine; Cancer; Pharmacokinetics; Adverse effect; Biology; Histone","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001888893,0.001514424,0.001813615,0.000584059,0.000482383,0.001063408,0.001053477,0.001731321,0.008245935],"category_scores_gemma":[0.0008545044,0.000592313,0.001330935,0.0005655403,0.001293296,0.001095128,0.0003358148,0.004425199,0.001844427],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001128202,"about_ca_system_score_gemma":0.002271299,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001189084,"about_ca_topic_score_gemma":0.002817899,"domain_scores_codex":[0.9995067,0.000191763,0.00002365879,0.00006919247,0.00006191841,0.0001466157],"domain_scores_gemma":[0.999254,0.00009200608,0.0001468791,0.00008215688,0.00006707822,0.0003577927],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6137385,0.1707686,0.00409942,0.001102253,0.0008076233,0.0002923578,0.0002907846,0.002826476,0.09122703,0.0006574203,0.009853416,0.104336],"study_design_scores_gemma":[0.4720347,0.5152177,0.004079638,0.00003637863,0.000190013,0.0001729618,0.0000467167,0.0009396689,0.004283809,0.0002512145,0.002721691,0.00002557141],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9810833,0.001503837,0.00117318,0.0007771161,0.0001949928,0.009155325,0.00260379,0.0002974037,0.003211136],"genre_scores_gemma":[0.9691902,0.001691666,0.004526903,0.0023494,0.0002280369,0.010194,0.004200832,0.0001027497,0.007516106],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008245935,"threshold_uncertainty_score":0.02758545,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04596986603111417,"score_gpt":0.4208900314256666,"score_spread":0.3749201653945524,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}